Lymphoma Daily
Content directly from sources and does not necessarily reflect my views by Jason R Westin
Related Articles
Cancer of Unknown Primary (CUP)
Learn about effective cancer of unknown primary treatments with the fewest side effects. Customized options: surgery, chemotherapy, radiation therapy, proton therapy.
Advocacy Summit on Capitol Hill
Your voice matters. As oncologists, you are uniquely qualified to communicate with Congress about effective policies for the treatment of patients with cancer and the…
Advocacy Summit on Capitol Hill
Your voice matters. As oncologists, you are uniquely qualified to communicate with Congress about effective policies for the treatment of patients with cancer and the…
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper
Recommendations from the British Society of Haematology regarding bleomycin pulmonary toxicity (BPT) in classical Hodgkin lymphoma (CHL) centre around (1) appropriate patient selection, (2) routine…
Advocacy Summit on Capitol Hill
Your voice matters. As oncologists, you are uniquely qualified to communicate with Congress about effective policies for the treatment of patients with cancer and the…
Jason Westin: Advocacy is a year round opportunity to fight for our patients – OncoDaily
Ishwaria Subbiah shared a post on X: “Hear hear! There’s nothing more powerful than turning the power of your voice into action! Check out the…
CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL
Key Points. CNS relapse rate in HGBCL-DH-BCL2 (6.8% at 2 years) is much lower than previously reported and is associated with clinical risk factors.DZsig r
CNS Relapse in High-Grade B-cell Lymphoma with MYC and BCL2 Rearrangements and Dark-Zone Signature-Expressing DLBCL
Key Points. CNS relapse rate in HGBCL-DH-BCL2 (6.8% at 2 years) is much lower than previously reported and is associated with clinical risk factors.DZsig r
Advocacy Summit on Capitol Hill
Your voice matters. As oncologists, you are uniquely qualified to communicate with Congress about effective policies for the treatment of patients with cancer and the…
Advocacy Summit on Capitol Hill
Your voice matters. As oncologists, you are uniquely qualified to communicate with Congress about effective policies for the treatment of patients with cancer and the…